{"id":"W2889751375","doi":"10.1200/jco.2017.35.15_suppl.5547","title":"Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Ovarian cancer; Population; Folate receptor; Oncology; Nausea; Phases of clinical research; Dosing; Clinical trial; Cancer; Gastroenterology; Cancer cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002291258,0.0005049519,0.0008067656,0.0004096698,0.000173643,0.0004182942,0.0002716885,0.0002989427,0.001112631],"category_scores_gemma":[0.001375757,0.0002378191,0.0009069428,0.0005093274,0.0002465782,0.0002935816,0.0004310168,0.000539212,0.0002204491],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005756516,"about_ca_system_score_gemma":0.0006930669,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005244843,"about_ca_topic_score_gemma":0.00166801,"domain_scores_codex":[0.9994588,0.0002698325,0.00004377519,0.0001056414,0.00007712935,0.00004484539],"domain_scores_gemma":[0.9995648,0.00009728127,0.0001446264,0.00006074356,0.00004301297,0.00008948161],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3330349,0.01112102,0.2021726,0.001921882,0.01342726,0.0005854478,0.0007938253,0.005318878,0.1173357,0.0002662602,0.005271581,0.3087506],"study_design_scores_gemma":[0.1044321,0.3731624,0.4497817,0.0001492623,0.01671689,0.002725105,0.0002674944,0.003976248,0.03739281,0.0003217409,0.01100465,0.00006952987],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949451,0.002537034,0.0006490269,0.00005052292,0.00001084583,0.0005554774,0.0005983877,0.00003544778,0.0006181988],"genre_scores_gemma":[0.9961826,0.0007638767,0.0008029587,0.0001006739,0.00002631101,0.0003032576,0.001437003,0.000008417125,0.000374729],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002291258,"threshold_uncertainty_score":0.01211751,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08919688874973307,"score_gpt":0.4818670002204941,"score_spread":0.392670111470761,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}